scispace - formally typeset
Y

Yves Pommier

Researcher at National Institutes of Health

Publications -  847
Citations -  65543

Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.

Papers
More filters
Journal ArticleDOI

Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.

TL;DR: In this article, the effect of ET-743 on the Ewing sarcoma family of tumors (ESFTs) has been investigated and it has been shown that EWS-FLI1-based cell lines are more sensitive to treatment compared with other tumor types.
Journal ArticleDOI

New Approaches to SCLC Therapy: From the Laboratory to the Clinic

John T. Poirier, +46 more
TL;DR: This review largely summarizes work presented at the Third Biennial IASLC Small Cell Lung Cancer Meeting and identifies key knowledge gaps that should be addressed in order to advance the field in pursuit of reduced small cell lung cancer mortality.
Journal ArticleDOI

Retroviral integrase inhibitors year 2000 : update and perspectives

TL;DR: There are now several inhibitors with known sites of actions and antiviral activity, the challenge is to convert these leads into drugs that will selectively target integrase in vivo, and can be added to the antiviral armamentarium.
Journal ArticleDOI

Mechanism of Inhibition of HIV-1 Integrase by G-tetrad-forming Oligonucleotides in Vitro

TL;DR: The G-tetrad-forming oligonucleotides T30177 and T30695 have been identified as potent inhibitors of human immunodeficiency virus type 1 integrase activity and docking results show a high probability of interaction between the GTGT loop residues of the G-quartet inhibitors and the catalytic site of HIV-1 IN, in agreement with the experimental observation.
Journal ArticleDOI

HIV-1 IN inhibitors: 2010 update and perspectives.

TL;DR: An update on the IN inhibitors reported in the last two years, including second generation STI, recently developed hydroxylated aromatics, natural products, peptide, antibody and oligonucleotide inhibitors, and the targeting of IN cofactors such as LEDGF and Vpr will be discussed as novel strategies for the treatment of AIDS.